II Medizinische Klinik, Technische Universität München, 81675 Munich, Germany.
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9945-50. doi: 10.1073/pnas.1100890108. Epub 2011 May 31.
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor patient outcome often resulting from late diagnosis in advanced stages. To date methods to diagnose early-stage PDAC are limited and in vivo detection of pancreatic intraepithelial neoplasia (PanIN), a preinvasive precursor of PDAC, is impossible. Using a cathepsin-activatable near-infrared probe in combination with flexible confocal fluorescence lasermicroscopy (CFL) in a genetically defined mouse model of PDAC we were able to detect and grade murine PanIN lesions in real time in vivo. Our diagnostic approach is highly sensitive and specific and proved superior to clinically established fluorescein-enhanced imaging. Translation of this endoscopic technique into the clinic should tremendously improve detection of pancreatic neoplasia, thus reforming management of patients at risk for PDAC.
胰腺导管腺癌 (PDAC) 是一种致命疾病,患者预后不良,通常是由于晚期诊断所致。迄今为止,诊断早期 PDAC 的方法有限,并且无法在体内检测胰腺上皮内瘤变 (PanIN),后者是 PDAC 的一种侵袭前前体。我们使用组织蛋白酶激活型近红外探针结合柔性共聚焦荧光激光显微镜 (CFL),在 PDAC 的基因定义小鼠模型中,能够实时体内检测和分级小鼠 PanIN 病变。我们的诊断方法具有高度的敏感性和特异性,优于临床现有的荧光素增强成像。将这种内镜技术转化为临床应用,应该会极大地提高胰腺肿瘤的检测率,从而改变 PDAC 高危患者的管理方式。